Suboxone

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

buprenorphine, naloxone

Available from:

Indivior Europe Limited

ATC code:

N07BC51

INN (International Name):

buprenorphine, naloxone

Therapeutic group:

Drogi oħra tas-sistema nervuża

Therapeutic area:

Disturbi Relatati ma 'Opjojdi

Therapeutic indications:

Trattament ta 'sostituzzjoni għal dipendenza fuq opioid-drug, fi ħdan qafas ta' trattament mediku, soċjali u psikoloġiku. L-intenzjoni tal-komponent ta 'naloxone hija li tiskoraġġixxi l-użu ħażin minn ġol-vina. Il-kura hija maħsuba għall-użu f'adulti u adolexxenti ta 'aktar minn 15-il sena li qablu li jiġu ttrattati għall-vizzju.

Product summary:

Revision: 22

Authorization status:

Awtorizzat

Authorization date:

2006-09-26

Patient Information leaflet

                                65
B. FULJETT TA’ TAGĦRIF
66
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-UTENT
SUBOXONE 2 MG/0.5 MG PILLOLI GĦAL TAĦT L-ILSIEN
SUBOXONE 8 MG/2 MG PILLOLI GĦAL TAĦT L-ILSIEN
SUBOXONE 16 MG/4 MG PILLOLI GĦAL TAĦT L-ILSIEN
buprenorphine / naloxone
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TIEĦU DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK.
-
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
-
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib jew lill-ispiżjar
tiegħek.
-
Din il-mediċina ġiet mogħtija lilek biss. M’għandekx tgħaddiha
lil persuni oħra. Tista’
tagħmlilhom il-ħsara anke jekk għandhom l-istess sinjali ta’ mard
bħal tiegħek.
-
Jekk ikollok xi effett sekondarju, kellem lit-tabib jew lill-ispiżjar
tiegħek. Dan jinkludi xi effett
sekondarju possibbli li mhuwiex elenkat f’dan il-fuljett. Ara
sezzjoni 4.
F’DAN IL-FULJETT
1.
X’inhu Suboxone u għalxiex jintuża
2.
X’għandek tkun taf qabel ma tieħu Suboxone
3.
Kif għandek tieħu Suboxone
4.
Effetti sekondarji possibbli
5
Kif taħżen Suboxone
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU SUBOXONE U GĦALXIEX JINTUŻA
Suboxone jintuża biex jikkura d-dipendenza fuq mediċini opjojdi
(narkotiċi) bħal eroina jew morfina
f’persuni dipendenti fuq id-droga li jkunu qablu li jiġu kkurati
għall-vizzju tagħhom. Suboxone jintuża
f’persuni adulti u adolexxenti li għandhom iktar minn 15-il sena,
li jkunu qed jirċievu wkoll appoġġ
mediku, soċjali u psikoloġiku.
2.
X’GĦANDEK TKUN TAF QABEL MA TIEĦU SUBOXONE
TIĦUX SUBOXONE
•
Jekk inti
ALLERĠIKU
għal
BUPRENORPHINE, NALOXONE
jew għal xi sustanza oħra ta’ din il-mediċina
(imniżżla fis-sezzjoni 6)
•
jekk għandek
PROBLEMI RESPIRATORJI SERJI
•
jekk għandek
PROBLEMI SERJI TAL-FWIED
•
jekk inti tkun fis-sakra minħabba l-alkoħol jew ikollok ir-rogħda,
għaraq, ansjetà, konfużjoni,
jew alluċinazzjonijiet ikkawżati mill-alkoħol.
•
jekk qed tieħu naltrexone jew nalmefene għal-kura ta’ dipendenza
fuq 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT MEDIĊINALI
Suboxone 2 mg/0.5 mg pilloli għal taħt l-ilsien
Suboxone 8 mg/2 mg pilloli għal taħt l-ilsien
Suboxone 16 mg/4 mg pilloli għal taħt l-ilsien
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Suboxone 2 m
g/0.5 mg pilloli għal taħt l-ilsien
Kull pillola għal taħt l-ilsien fiha 2 mg ta’ buprenorphine
(bħala hydrochloride) u 0.5 mg ta’ naloxone
(bħala hydrochloride dihydrate).
Eċċipjenti b’effett magħruf:
Kull pillola għal taħt l-ilsien fiha 42 mg ta’ lactose (bħala
monoidrat)
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
Suboxone 8 mg/2 mg pilloli għal taħt l-ilsien
Kull pillola għal taħt l-ilsien fiha 8 mg ta’ buprenorphine
(bħala hydrochloride) u 2 mg ta’ naloxone
(bħala hydrochloride dihydrate).
Eċċipjenti b’effett magħruf:
Kull pillola għal taħt l-ilsien fiha 168 mg ta’ lactose (bħala
monoidrat)
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
Suboxone 16 mg/4 mg pilloli għal taħt l-ilsien
Kull pillola għal taħt l-ilsien fiha 16 mg ta’ buprenorphine
(bħala hydrochloride) u 4 mg ta’ naloxone
(bħala hydrochloride dihydrate).
Eċċipjenti b’effett magħruf:
Kull pillola għal taħt l-ilsien fiha 156.64 mg ta’ lactose (bħala
monoidrat)
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola għal taħt l-ilsien
Suboxone 2 m
g/0.5 mg pilloli għal taħt l-ilsien
Pilloli bojod bikonvessi eżagonali ta’ 6.5 mm b’“N2” imnaqqxa
fuq naħa waħda.
Suboxone 8 mg/2 mg pilloli għal taħt l-ilsien
Pilloli bojod bikonvessi eżagonali ta’ 11 mm b’“N8” imnaqqxa
fuq naħa waħda.
Suboxone 16 mg
/4 mg pilloli għal taħt l-ilsien
Pilloli bojod bikonvessi tondi ta’10.5 mm b’“N16” imnaqqxa fuq
naħa waħda.
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Kura ta’ sostituzzjoni għal dipendenza fuq mediċini opjojdi,
fil-qafas ta’ kura medika, soċjali u
psikoloġika. L-intenzjoni tal-komponent naloxone hu biex
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 20-11-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 20-11-2023
Public Assessment Report Public Assessment Report Bulgarian 28-07-2020
Patient Information leaflet Patient Information leaflet Spanish 20-11-2023
Public Assessment Report Public Assessment Report Spanish 28-07-2020
Patient Information leaflet Patient Information leaflet Czech 20-11-2023
Public Assessment Report Public Assessment Report Czech 28-07-2020
Patient Information leaflet Patient Information leaflet Danish 20-11-2023
Public Assessment Report Public Assessment Report Danish 28-07-2020
Patient Information leaflet Patient Information leaflet German 20-11-2023
Public Assessment Report Public Assessment Report German 28-07-2020
Patient Information leaflet Patient Information leaflet Estonian 20-11-2023
Public Assessment Report Public Assessment Report Estonian 28-07-2020
Patient Information leaflet Patient Information leaflet Greek 20-11-2023
Public Assessment Report Public Assessment Report Greek 28-07-2020
Patient Information leaflet Patient Information leaflet English 20-11-2023
Public Assessment Report Public Assessment Report English 28-07-2020
Patient Information leaflet Patient Information leaflet French 20-11-2023
Public Assessment Report Public Assessment Report French 28-07-2020
Patient Information leaflet Patient Information leaflet Italian 20-11-2023
Public Assessment Report Public Assessment Report Italian 28-07-2020
Patient Information leaflet Patient Information leaflet Latvian 20-11-2023
Public Assessment Report Public Assessment Report Latvian 28-07-2020
Patient Information leaflet Patient Information leaflet Lithuanian 20-11-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 20-11-2023
Public Assessment Report Public Assessment Report Lithuanian 28-07-2020
Patient Information leaflet Patient Information leaflet Hungarian 20-11-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 20-11-2023
Public Assessment Report Public Assessment Report Hungarian 28-07-2020
Patient Information leaflet Patient Information leaflet Dutch 20-11-2023
Public Assessment Report Public Assessment Report Dutch 28-07-2020
Patient Information leaflet Patient Information leaflet Polish 20-11-2023
Public Assessment Report Public Assessment Report Polish 28-07-2020
Patient Information leaflet Patient Information leaflet Portuguese 20-11-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 20-11-2023
Public Assessment Report Public Assessment Report Portuguese 28-07-2020
Patient Information leaflet Patient Information leaflet Romanian 20-11-2023
Public Assessment Report Public Assessment Report Romanian 28-07-2020
Patient Information leaflet Patient Information leaflet Slovak 20-11-2023
Public Assessment Report Public Assessment Report Slovak 28-07-2020
Patient Information leaflet Patient Information leaflet Slovenian 20-11-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 20-11-2023
Public Assessment Report Public Assessment Report Slovenian 28-07-2020
Patient Information leaflet Patient Information leaflet Finnish 20-11-2023
Public Assessment Report Public Assessment Report Finnish 28-07-2020
Patient Information leaflet Patient Information leaflet Swedish 20-11-2023
Public Assessment Report Public Assessment Report Swedish 28-07-2020
Patient Information leaflet Patient Information leaflet Norwegian 20-11-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 20-11-2023
Patient Information leaflet Patient Information leaflet Icelandic 20-11-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 20-11-2023
Patient Information leaflet Patient Information leaflet Croatian 20-11-2023
Public Assessment Report Public Assessment Report Croatian 28-07-2020

Search alerts related to this product

View documents history